UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
PHARMACEUTICAL COMPANIES

ANI Pharmaceuticals

Rare disease and established pharmaceutical products maker

ANI Pharmaceuticals logo

ANI Pharmaceuticals

Pharmaceutical CompaniesBaudette, MN, United States

Rare disease and established pharmaceutical products maker

Visit Website

About ANI Pharmaceuticals

ANI Pharmaceuticals is a NASDAQ-listed integrated specialty pharmaceutical company (ticker: ANIP) focused on building a leading rare disease business. Operating across branded and generic prescription markets, the company develops, manufactures, and markets high-quality pharmaceuticals for patients with significant unmet needs.

The company's rare disease focus is a defining strategic pillar, with FDA-approved products including Cortrophin serving as a flagship within its branded portfolio. ANI also operates a generics and other pharmaceuticals segment, broadening its commercial reach across multiple therapeutic categories.

Manufacturing is a core competency. ANI offers contract manufacturing capabilities alongside its proprietary product lines, with quality systems and production facilities supporting both its own pipeline and third-party clients. Its operational footprint includes facilities in Baudette, Minnesota, and additional locations expanded through the acquisition of Novitium Pharma, which is now fully integrated into the ANI business.

The company maintains a medical information portal for both its branded rare disease products and its generics range, reflecting a commitment to supporting healthcare professionals with accurate prescribing resources. ANI reported first quarter 2026 financial results in May 2026 and raised its full-year 2026 financial guidance, signalling continued commercial momentum. The company was also scheduled to present at the 2026 Jefferies Global Healthcare Conference in May 2026.

Further information is available at anipharmaceuticals.com.

Areas of Expertise

Branded PharmaceuticalsContract ManufacturingDrug DevelopmentGeneric PharmaceuticalsRare DiseaseSpecialty Pharma

Services & Capabilities

Branded PharmaceuticalsContract ManufacturingDrug DevelopmentGeneric PharmaceuticalsRare DiseaseSpecialty Pharma
Similar Companies

More in Pharmaceutical Companies

A

Allergy Therapeutics

Allergy Therapeutics positions itself as a global pioneer of convenient treatment for allergy and immune-related disorders, operating as a publicly listed company (PLC) with commercial presence across Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. A declared focus on patient convenience runs throughout the company's scientific and commercial model. The organisation frames convenience not as a secondary benefit but as a clinical imperative, recognising that treatment adherence in allergy immunotherapy depends on how manageable the regimen is for both healthcare professionals and patients. Its research and development programme reflects this, combining product development with a published body of investigator and consultant registry data. The company's adjuvant technology is commercialised through its Bencard Adjuvant Systems division, which sits alongside the core Allergy Therapeutics brand as a specialist unit serving healthcare partners and industry stakeholders. This dual structure signals a role that extends beyond direct-to-clinician supply into platform licensing and scientific collaboration. Investor-facing materials describe a defined business model, investment case, and strategy, consistent with a company that reports to public markets and maintains structured shareholder services. The breadth of its European footprint and the existence of a dedicated healthcare professional information channel indicate an established B2B and clinical relationships network. Further information is available at allergytherapeutics.com.

View profile
A

AOP Orphan

Europe's pioneer in integrated therapies for rare diseases and critical care, AOP Health (trading as AOP Orphan) brings together scientific rigour, clinical development and commercial delivery under one roof. The company operates at the intersection of rare disease medicine and intensive-care medicine, two areas where unmet patient need remains exceptionally high. The therapeutic focus spans cardiology and pulmonology, haemato-oncology, critical care, and advanced therapies. This breadth reflects a deliberate strategy to address conditions that are either underserved by mainstream pharmaceutical investment or require highly specialised clinical management. A patient story programme, including accounts of sepsis survival, illustrates the real-world impact the company seeks to communicate to partners, prescribers and policymakers alike. On the scientific side, AOP Health maintains an active clinical pipeline with new trials entering development, including a study of a novel treatment approach for blood cancers announced in June 2026. The company publishes its research findings and makes its innovation methodology available to industry audiences, reflecting an openness to scientific dialogue that is characteristic of organisations working in rare-disease areas subject to close regulatory scrutiny. AOP Health operates across multiple international locations and participates actively in the global congress calendar, including rare skin disease and haemato-oncology meetings. In June 2026, the company received a Gold award at the WKO Export Awards, recognising its performance as an Austrian exporter with international reach. This recognition underlines its standing as a commercially active, internationally operating pharmaceutical business, not merely a research-stage organisation. Further information is available at aop-health.com.

View profile
M

Merz Aesthetics

Merz Aesthetics is the dedicated aesthetics division of Merz Pharmaceuticals, a family-owned German healthcare company with roots stretching back to 1908. Where many aesthetics companies are relatively young, Merz brings more than a century of pharmaceutical heritage to a sector it has helped define.The division focuses exclusively on medical aesthetics, offering a portfolio spanning neurotoxins, dermal fillers, and energy-based device technologies. Its neurotoxin brand Xeomin (incobotulinumtoxinA) is approved in multiple markets for both aesthetic and therapeutic indications, and is notable for its purified formulation, which contains no complexing proteins. The Belotero range of hyaluronic acid fillers addresses a broad spectrum of facial rejuvenation needs, from fine lines to volumisation.Merz Aesthetics operates globally, with a significant commercial presence across North America, Europe, and Asia-Pacific. The division is headquartered in Raleigh, North Carolina, reflecting the strategic importance of the United States as its largest aesthetics market, while its parent company remains based in Frankfurt, Germany.Beyond injectables, the company has expanded into energy-based devices through partnerships and acquisitions, broadening its offering to aesthetic practitioners who seek a more comprehensive treatment portfolio. Its education and training programmes for healthcare professionals are a recognised part of its commercial model, supporting clinical best practice alongside product adoption.As a privately held entity within the Merz family group, the division is not publicly listed, allowing a longer-term investment horizon than many listed peers. This structure has supported sustained investment in clinical evidence and product development across its core categories.Further information is available at merzaesthetics.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy